Principal Financial Group Inc. Sells 3,743 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Principal Financial Group Inc. trimmed its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 3.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 119,726 shares of the company’s stock after selling 3,743 shares during the period. Principal Financial Group Inc. owned approximately 0.42% of Krystal Biotech worth $21,794,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of KRYS. State Street Corp lifted its stake in Krystal Biotech by 9.0% in the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after acquiring an additional 119,936 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Krystal Biotech by 2.0% in the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock worth $107,714,000 after purchasing an additional 11,411 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Krystal Biotech by 1.3% during the second quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock worth $106,593,000 after purchasing an additional 7,537 shares during the last quarter. Hood River Capital Management LLC grew its position in Krystal Biotech by 5.1% in the second quarter. Hood River Capital Management LLC now owns 521,093 shares of the company’s stock valued at $95,694,000 after purchasing an additional 25,507 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in Krystal Biotech by 34.2% in the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after buying an additional 62,178 shares during the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on KRYS shares. Stifel Nicolaus lifted their target price on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Chardan Capital reiterated a “buy” rating and set a $212.00 price objective on shares of Krystal Biotech in a research note on Wednesday, December 18th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Wednesday, December 18th. Finally, William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $206.67.

Krystal Biotech Stock Down 1.4 %

Shares of NASDAQ:KRYS opened at $158.52 on Thursday. Krystal Biotech, Inc. has a 12-month low of $107.50 and a 12-month high of $219.34. The business has a 50 day moving average of $179.41 and a 200-day moving average of $185.22. The stock has a market cap of $4.56 billion, a PE ratio of 89.56 and a beta of 0.80.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. During the same period in the prior year, the firm posted ($0.67) EPS. The company’s revenue for the quarter was up 879.9% on a year-over-year basis. Equities research analysts expect that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 14.10% of the stock is owned by company insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).